Gastric cancer is molecularly heterogeneous—HER2 amplification, CLDN18.2 expression, MSI-H/EBV-positive subsets link to immunotherapy; H pylori-driven inflammation contributes to carcinogenesis. We provide HER2/CLDN18.2/PD-L1 antibodies plus anti-angiogenic and MAPK/PI3K probes for perioperative, peritoneal, and combination studies.
Focus areas: HER2/CLDN18.2 & ADCs, peritoneal metastasis models, MSI/EBV immune subsets, neoadjuvant biomarkers
Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.
| Compound | Targets / pathways | Experimental notes |
|---|---|---|
| Trastuzumab (anti-HER2 mAb) | HER2 | Standard in HER2+ models; baseline cardiac monitoring. |
| Trastuzumab deruxtecan (ADC) | HER2 ADC | Bystander effect; ILD risk—careful animal translation. |
| Ramucirumab (anti-VEGFR2 mAb) | VEGFR2 | Second-line anti-angiogenesis mapping; bleeding/wound risk. |
| Apatinib | VEGFR2 | Small-molecule anti-angiogenesis; proteinuria/BP. |
| Trametinib | MEK1/2 | MAPK bypass probe; sequential HER2 combinations. |
| 5-Fluorouracil | TS / DNA synthesis | Perioperative/peritoneal backbone; read with MMR status. |
| Cisplatin | DNA crosslink | Neoadjuvant backbone; manage nephro/neurotoxicity. |